Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in prostate cancer undergoing intermittent ADT
NCT00686036Phase 2Terminated
- Sponsor
- Sanofi
- Start
- May 2008
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Vandetanib with Placebo (2 arms). Primary endpoint: Number of Participants Not Reaching a PSA >= 5ng/mL by 52 Weeks During the Off-treatment Phase of Androgen Deprivation Therapy (ADT). Started May 2008; status: terminated.
02
Drugs
vandetanib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00686036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00686036.